- +1 858 909 0079
- +1 858 909 0057
- [email protected]
- +1 858 909 0079
- [email protected]
Cat# | Products (Recombinant protein) | Swiss Prot# | Size | Price (US$) | Order |
PL0110 | Recombinant protein-Brugia malayi Gp 15-400 antigen (a.a.1 to 132) | Q26405 | 100 µg | 1195 | |
PL0111 | Recombinant protein-Brugia malayi Filarial antigen (a.a.30 to 461) | Q26442 | 100 µg | 1195 | |
PL0112 | Recombinant protein-Brugia malayi Major antigen (a.a.30 to 255) | A8NZB4 | 100 µg | 1195 | |
PL0113 | Recombinant protein-Brugia malayi Collagen-like antigen (a.a.30 to 452) | Q17189 | 100 µg | 1195 | |
PL0114 | Recombinant protein-Brugia malayi Interspersed repeat antigen (a.a.30 to 386) | A8NLR3 | 100 µg | 1195 | |
PL0115 | Recombinant protein-Brugia malayi LL20 15kDa ladder antigen (a.a.61 to 460) | A8QEB0 | 100 µg | 1195 | |
PL0116 | Recombinant protein-Brugia malayi Sarcoma antigen NY-SAR-91(a.a.1 to 136) | A8NU33 | 100 µg | 1195 | |
PL0117 | Recombinant protein-Brugia malayi Major surface protein 3(a.a.30 to 294) | A8PZD8 | 100 µg | 1195 | |
PL0118 | Recombinant protein-Brugia malayi CLL-associated antigen KW-2(a.a.30 to 480) | A8PQV9 | 100 µg | 1195 | |
PL0119 | Recombinant protein-Brugia malayi Proliferating cell nuclear antigen (a.a.30 to 264) | A8PV43 | 100 µg | 1195 | |
PL0120 | Recombinant protein-Brugia malayi OV39 antigen-like (a.a.1 to 135) | A8NVF8 | 100 µg | 1195 | |
PL0121 | Recombinant protein-Brugia malayi Cutaneous T-cell lymphoma tumor antigen se70-2(a.a.61 to 460) | A8Q8D6 | 100 µg | 1195 | |
PL0122 | Recombinant protein-Brugia malayi Recombinant antigen R1 (a.a.26 to 206) | Q71TT6 | 100 µg | 1195 | |
PL0123 | Recombinant protein-Brugia malayi S-antigen protein (a.a.30 to 262) | A8NI25 | 100 µg | 1195 | |
PL0124 | Recombinant protein-Brugia malayi Antigen (a.a.15 to 155) | A8Q4D7 | 100 µg | 1195 | |
PL0125 | Recombinant protein-Brugia malayi Filarial antigen Av33 (a.a.21 to 223) | A8Q4E4 | 100 µg | 1195 | |
PL0126 | Recombinant protein-Brugia malayi Antigen-L3SXP (a.a.17 to 153) | A8Q4D9 | 100 µg | 1195 | |
PL0127 | Recombinant protein-Brugia malayi Venom allergen antigen-like protein 1 (a.a.30 to 220) | O44932 | 100 µg | 1195 | |
PL0128 | Recombinant protein-Brugia malayi Microfilariae surface-associated protein (a.a.21 to 107) | A8NFN8 | 100 µg | 1195 | |
PL0129 | Recombinant protein-Brugia malayi Membrane-anchored cell surface protein (a.a.20 to 250) | A8Q5R4 | 100 µg | 1195 | |
PL0130 | Recombinant protein-Brugia malayi Recombinant antigen R1- identical (a.a.22 to 203) | A8NW22 | 100 µg | 1195 | |
PL0131 | Recombinant protein-Brugia malayi Immunodominant antigen homologue (a.a.61 to 460) | A8PQT5 | 100 µg | 1195 | |
PL0132 | Recombinant protein-Brugia malayi Serologically defined colon cancer antigen 1(a.a.19 to 307) | A8NVV9 | 100 µg | 1195 | |
PL0133 | Recombinant protein-Brugia malayi Cuticular glycoprotein gp29 (a.a.26 to 223) | P67877 | 100 µg | 1195 | |
PL0134 | Recombinant protein-Brugia malayi Hepatocellular carcinoma-associated antigen 66(a.a.1 to 103) | A8NUF5 | 100 µg | 1195 | |
PL0135 | Recombinant protein-Brugia malayi IgG and IgE immunoreactive antigen (a.a.14 to 175) | A8NZ92 | 100 µg | 1195 | |
PL0136 | Recombinant protein-Brugia malayi Hepatocellular carcinoma-associated antigen (a.a.30 to 426) | A8NKY4 | 100 µg | 1195 | |
PL0137 | Recombinant protein-Brugia malayi Serologically defined breast cancer antigen (a.a.30 to 341) | A8PT78 | 100 µg | 1195 | |
PL0138 | Recombinant protein-Brugia malayi OV-16 antigen (a.a.20 to 185) | A8Q2C4 | 100 µg | 1195 | |
PL0139 | Recombinant protein-Brugia malayi Octapeptide-repeat antigen (a.a.25 to 111) | A8PMZ0 | 100 µg | 1195 | |
PL0140 | Recombinant protein-Brugia malayi 60K filarial antigen-nematode (a.a.30 to 491) | A8QF57 | 100 µg | 1195 | |
PL0141 | Recombinant protein-Brugia malayi Merozoite surface protein 2(a.a.14 to 149) | A8PIT0 | 100 µg | 1195 | |
RPL0110 | cDNA-Brugia malayi Gp 15-400 antigen (a.a.1 to 132) | Q26405 | 2 µg | 786 | |
RPL0111 | cDNA-Brugia malayi Filarial antigen (a.a.30 to 461) | Q26442 | 2 µg | 2586 | |
RPL0112 | cDNA-Brugia malayi Major antigen (a.a.30 to 255) | A8NZB4 | 2 µg | 1350 | |
RPL0113 | cDNA-Brugia malayi Collagen-like antigen (a.a.30 to 452) | Q17189 | 2 µg | 2532 | |
RPL0114 | cDNA-Brugia malayi Interspersed repeat antigen (a.a.30 to 386) | A8NLR3 | 2 µg | 2136 | |
RPL0115 | cDNA-Brugia malayi LL20 15kDa ladder antigen (a.a.61 to 460) | A8QEB0 | 2 µg | 2394 | |
RPL0116 | cDNA-Brugia malayi Sarcoma antigen NY-SAR-91(a.a.1 to 136) | A8NU33 | 2 µg | 810 | |
RPL0117 | cDNA-Brugia malayi Major surface protein 3(a.a.30 to 294) | A8PZD8 | 2 µg | 1584 | |
RPL0118 | cDNA-Brugia malayi CLL-associated antigen KW-2(a.a.30 to 480) | A8PQV9 | 2 µg | 2700 | |
RPL0119 | cDNA-Brugia malayi Proliferating cell nuclear antigen (a.a.30 to 264) | A8PV43 | 2 µg | 1404 | |
RPL0120 | cDNA-Brugia malayi OV39 antigen-like (a.a.1 to 135) | A8NVF8 | 2 µg | 804 | |
RPL0121 | cDNA-Brugia malayi Cutaneous T-cell lymphoma tumor antigen se70-2(a.a.61 to 460) | A8Q8D6 | 2 µg | 2394 | |
RPL0122 | cDNA-Brugia malayi Recombinant antigen R1 (a.a.26 to 206) | Q71TT6 | 2 µg | 1080 | |
RPL0123 | cDNA-Brugia malayi S-antigen protein (a.a.30 to 262) | A8NI25 | 2 µg | 1392 | |
RPL0124 | cDNA-Brugia malayi Antigen (a.a.15 to 155) | A8Q4D7 | 2 µg | 840 | |
RPL0125 | cDNA-Brugia malayi Filarial antigen Av33 (a.a.21 to 223) | A8Q4E4 | 2 µg | 1212 | |
RPL0126 | cDNA-Brugia malayi Antigen-L3SXP (a.a.17 to 153) | A8Q4D9 | 2 µg | 816 | |
RPL0127 | cDNA-Brugia malayi Venom allergen antigen-like protein 1 (a.a.30 to 220) | O44932 | 2 µg | 1140 | |
RPL0128 | cDNA-Brugia malayi Microfilariae surface-associated protein (a.a.21 to 107) | A8NFN8 | 2 µg | 800 | |
RPL0129 | cDNA-Brugia malayi Membrane-anchored cell surface protein (a.a.20 to 250) | A8Q5R4 | 2 µg | 1380 | |
RPL0130 | cDNA-Brugia malayi Recombinant antigen R1- identical (a.a.22 to 203) | A8NW22 | 2 µg | 1086 | |
RPL0131 | cDNA-Brugia malayi Immunodominant antigen homologue (a.a.61 to 460) | A8PQT5 | 2 µg | 2394 | |
RPL0132 | cDNA-Brugia malayi Serologically defined colon cancer antigen 1(a.a.19 to 307) | A8NVV9 | 2 µg | 1728 | |
RPL0133 | cDNA-Brugia malayi Cuticular glycoprotein gp29 (a.a.26 to 223) | P67877 | 2 µg | 1182 | |
RPL0134 | cDNA-Brugia malayi Hepatocellular carcinoma-associated antigen 66(a.a.1 to 103) | A8NUF5 | 2 µg | 800 | |
RPL0135 | cDNA-Brugia malayi IgG and IgE immunoreactive antigen (a.a.14 to 175) | A8NZ92 | 2 µg | 966 | |
RPL0136 | cDNA-Brugia malayi Hepatocellular carcinoma-associated antigen (a.a.30 to 426) | A8NKY4 | 2 µg | 2376 | |
RPL0137 | cDNA-Brugia malayi Serologically defined breast cancer antigen (a.a.30 to 341) | A8PT78 | 2 µg | 1866 | |
RPL0138 | cDNA-Brugia malayi OV-16 antigen (a.a.20 to 185) | A8Q2C4 | 2 µg | 990 | |
RPL0139 | cDNA-Brugia malayi Octapeptide-repeat antigen (a.a.25 to 111) | A8PMZ0 | 2 µg | 800 | |
RPL0140 | cDNA-Brugia malayi 60K filarial antigen-nematode (a.a.30 to 491) | A8QF57 | 2 µg | 2766 | |
RPL0141 | cDNA-Brugia malayi Merozoite surface protein 2(a.a.14 to 149) | A8PIT0 | 2 µg | 810 |
Brugia malayi cDNA and recombinant antigen
Brugia malayi is a filarial nematode that is transmitted by mosquitoes and causes lymphatic filariasis, a disease that can lead to debilitating swelling of the limbs and genitals. It is endemic to certain regions of the world and is a major public health concern in many developing countries.
Gp 15-400 antigen, major antigens, and filarial antigens are key targets in the development of diagnostic tests and vaccines for lymphatic filariasis. Some of the major antigens of Brugia malayi include collagen-like antigen, interspersed repeat antigen, LL20 15kDa ladder antigen, and sarcoma antigen NY-SAR-91. Filarial antigens such as Av33, major surface protein 3, CLL-associated antigen KW-2, proliferating cell nuclear antigen, OV39 antigen-like, recombinant antigen R1, S-antigen protein, L3SXP, venom allergen antigen-like protein 1, gp29, OV-16 antigen, and 60K filarial antigen-nematode are also potential targets for diagnostic tests and vaccines.
Understanding the function and interaction of the key antigens associated with Brugia malayi is crucial for the development of effective diagnostic tests and vaccines to prevent and control the spread of lymphatic filariasis.
The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.
Get the Latest News and Updates by Email
6393 Nancy Ridge Dr. Suite A
San Diego, CA 92121 USA
Fax: +1-858-909-0057
Get the Latest News and Updates by Email
© 2023 Bioclone Inc. All Rights Reserved.
Magnetic Beads Make Things Simple